Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm

The treatment of patients with moderate to severe Crohn’s disease [CD] is still challenging. Therapeutic options include steroids, immunosuppressants, anti-TNFα agents, vedolizumab, and ustekinumab. Ustekinumab is a monoclonal antibody blocking the p40 subunit of IL-12 and IL-23. It showed to be eff...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Ferdinando, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097676/
https://www.ncbi.nlm.nih.gov/pubmed/35553665
http://dx.doi.org/10.1093/ecco-jcc/jjac011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097676/
https://www.ncbi.nlm.nih.gov/pubmed/35553665
http://dx.doi.org/10.1093/ecco-jcc/jjac011

Ejemplares similares